

**NOTICE OF NEW HAMPSHIRE MEDICAID
DRUG USE REVIEW BOARD
PUBLIC HEARING**

June 15, 2011

The New Hampshire Drug Use Review (DUR) Board invites you to attend a public hearing at 3:00 p.m., on June 15, 2011 at the Brown Building – Auditorium, 129 Pleasant Street, Concord, NH. A DUR meeting will immediately follow this public hearing.

The purpose of the public hearing on June 15, 2011, is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid preferred drug list and pharmacy prior authorization criteria.

The public hearing will begin at 3:00 p.m. and end no later than 4:00 p.m. The DUR meeting will begin at or before 4:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the preferred drug list and prior authorization criteria for the June 15, 2011 public hearing. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the preferred drug list and prior authorization criteria.

Written material may also be submitted by the public for DUR Board consideration if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

**DRUG USE REVIEW BOARD MEETING
June 15, 2011
Meeting Agenda**

I. Old Business

- a. Minutes – 03/25/11 review

II. New Business

1. Review of Current Preferred Drug List Therapeutic Classes with No Proposed Changes
 - Behavioral Health
 - Alzheimer’s Agents
 - Anxiolytics
 - Novel Antidepressants
 - SSRI
 - Sedative Hypnotics
 - Antibiotics
 - 2nd generation Cephalosporins
 - 3rd generation Cephalosporins
 - 2nd generation Quinolones
 - 3rd generation Quinolones
 - Genitourinary/Renal
 - Alpha Blockers for Benign Prostatic Hyperplasia
 - Electrolyte Depleters
 - Antifungal
 - Onychomycosis
2. Review of Current Preferred Drug List Therapeutic Classes with Proposed Changes
 - Interferons Used to Treat Multiple Sclerosis
 - Bisphosphonates

3. Review of New Proposed Preferred Drug List Therapeutic Classes
 - Topical Antiparasitics
 - Pancreatic Enzymes
 - Smoking Cessations
 - Oral Anticoagulants
 - Topical Steroids (very high, high, medium, low potency)
 - Rectal Anticonvulsants
 - Multiple Sclerosis Agents
 - Osteoporosis Medications
4. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes
 - Bowel Disorder Medications®
5. Review of Current Clinical Prior Authorization Criteria with Proposed Changes
 - Suboxone®/Subutex®
 - Spiriva®
 - Multiple Sclerosis Agents
6. Review of New Proposed Clinical Prior Authorization Criteria
 - COPD Medications
7. Overview of Drug Utilization Patterns for New Hampshire Medicaid
 - Prospective DUR Reports
 - Utilization Reports
 - Retrospective DUR Reports

III. Adjourn

Further information regarding the agenda items may be obtained after May 25, 2011, by contacting Robin Calley, at 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: rlcalley@dhhs.state.nh.us.

Notice of intent to testify at the June 15, 2011 public hearing, and/or submittal of written comments, should be directed to Robin Calley, Office of Medicaid Business and Policy, 129 Pleasant Street, Concord, NH, 03301, 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: rlcalley@dhhs.state.nh.us.